Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

A Long-term Follow-up Study of FOLFIRINOX Regimen as Adjuvant Therapy in Pancreatic Cancer Patients After Curative Surgery: Multi-center, Prospective

This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.

This study is multi-center, prospective, long-term follow-up observational study.

Inclusion Criteria:

• Age over 19 at the time of obtaining the informed consent form
• Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
• ECOG 0 or 1
• Scheduled to RO or R1 resection
• Organ function capable of chemotherapy

Exclusion Criteria:

• FOLFIRINOX contraindications among the drug approval requirements
• Palliative Therapy
• Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX